Page
%P
-
Article
Open AccessImprovement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
Health-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis.
-
Article
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
Guselkumab effectively treats moderate-to-severe psoriasis.